Surrozen Presents Preliminary Results from Phase 1a Study of SZN-043 in Healthy Volunteers and Patients with a History of Liver Cirrhosis at the 2024 European Association for the Study of the Liver (EASL) in Milan

About Surrozen Treatment with SZN-043 in the Phase 1a trial was safe and well tolerated in healthy volunteers and patients with a history of liver cirrhosis Enrollment is ongoing in Phase 1b study in severe alcohol-associated hepatitis Study Overview Pharmacodynamic Biomarkers The study provided evidence of Wnt-mediated pharmacodynamic activity in the liver after treatment with SZN043. "We were pleased to present the first clinical data from this innovative bispecific antibody-based approach to modulating t ...